The findings provided new evidence that platinum-based chemotherapy could facilitate malignancy of carcinoma cells via activation of the EMT process by CNTN-1 overexpression other than their therapeutic effects, indicating that inhibiting the expression of CNTN-1 may reverse the EMT process and in turn, enhance the efficiency of platinum-based chemotherapy. The gene discussed is CNTN1; the disease is carcinoma.